Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 4/20 | 0.31 |
| ▸ | NPC1 | O15118 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21985357 | 0.80 | KMT2A (0.30) | LMNA | |
| SCHEMBL24400855 | 0.74 | CDK9 (0.30) | CDK9DYRK1A | |
| SCHEMBL17265835 | 0.73 | DYRK1A (0.34) | DYRK1A | |
| SCHEMBL13209494 | 0.67 | NQO2 (0.35) | KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL12930109 | 0.66 | CDK9 (0.39) | CDK9DYRK1AKDM4EALDH1A1LMNA | |
| SCHEMBL13916685 | 0.65 | KDM4E (0.67) | KDM4EALDH1A1LMNAMAPTPDGFRB | |
| SCHEMBL21959621 | 0.65 | HPGD (0.40) | KDM4EALDH1A1LMNAHTT | |
| SCHEMBL20936230 | 0.63 | CDK9 (0.40) | CDK9DYRK1AKDM4EALDH1A1LMNA | |
| SCHEMBL2067452 | 0.63 | HSD17B10 (0.47) | CDK9DYRK1AKDM4EALDH1A1LMNA | |
| SCHEMBL15300100 | 0.63 | DYRK1A (0.44) | CDK9DYRK1AKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11229208-B2 | Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents | SYNGENTA PARTICIPATIONS AG (CH) | 2022-01-25 | — | — | US | disclosed |
| US-10939682-B2 | Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents | SYNGENTA PARTICIPATIONS AG (CH) | 2021-03-09 | — | — | US | disclosed |
| US-20210037827-A1 | PESTICIDALLY ACTIVE BI- OR TRICYCLIC HETEROCYCLES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2021-02-11 | — | — | US | disclosed |
| US-20160255837-A1 | PESTICIDALLY ACTIVE BI- OR TRICYCLIC HETEROCYCLES WITH SULFUR CONTAINING SUBSTITUENTS | SYNGENTA PARTICIPATIONS AG (CH) | 2016-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160255837-A1 | PESTICIDALLY ACTIVE BI- OR TRICYCLIC HETEROCYCLES WITH SULFUR CONTAINING SUBSTITUENTS | DDT, TST, SCLY | CDK9 1791/4885DYRK1A 680/4885KDM4E 3403/4885 |
| US-20210037827-A1 | PESTICIDALLY ACTIVE BI- OR TRICYCLIC HETEROCYCLES WITH SULFUR CONTAINING SUBSTITUENTS | GSTA1, CYP1B1, DDT | CDK9 2005/4885DYRK1A 3346/4885KDM4E 3562/4885 |
| US-10939682-B2 | Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents | DDT, TST, SCLY | CDK9 1791/4885DYRK1A 680/4885KDM4E 3403/4885 |
| US-11229208-B2 | Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents | GSTA1, CYP1B1, DDT | CDK9 2005/4885DYRK1A 3346/4885KDM4E 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.